1. Home
  2. Faculty

Steven M Offer, PhD

Associate Professor of Pathology

Introduction

Dr. Steven Offer joined UI Pathology on January 8, 2024 as an Associate Professor. Dr. Offer received his Ph.D. in Molecular, Cellular, Developmental Biology & Genetics from the University of Minnesota in 2009. He then moved to Mayo Clinic to perform a post-doctoral fellowship in the area of pharmacogenomics where he became expert in incorporating computational biology in his work. Steven remained at Mayo Clinic as a Research Associate and was subsequently hired as an Assistant Professor in the Department of Molecular Pharmacology and Experimental Therapeutics. He was promoted to Associate Consultant in 2020. Dr. Offer's research focuses on cancer initiation and progression and utilizes a diverse array of cutting-edge biochemical, molecular, cellular, genetic, pharmacological and clinical methods to identify and characterize the changes that occur within cells to drive tumorigenesis and cancer metastasis.

Current Positions

  • Associate Professor - Pathology

Education

  • B.S. – Natural Sciences, University of Wisconsin–Madison, Madison, WI
  • Ph.D. – Molecular, Cellular, Developmental Biology & Genetics, University of Minnesota, Minneapolis, MN
  • Post-doctoral Fellow, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic
  • Research Associate, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic

Graduate Program Affiliations

Research Interests

  • Epigenetic contributions to tumor progression.
  • Drug resistance to cancer therapeutics.
  • Adverse toxicity to anti-cancer drugs.
  • Dihydropyrimidine dehydrogenase (DPD) deficiency as a pediatric disorder.

Selected Publications

  • Zhang T*, Ambrodji A, Huang H, Bouchonville KJ, Etheridge AS, Schmidt RE, Bembenek BM, Temesgen ZB, Wang Z, Innocenti F, Stroka D, Diasio RB, Largiadèr CR, Offer SM. Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD). bioRxiv. [Preprint]. 2023 Nov 4:2023.11.01.565230. PMID: 37961517 PMCID: PMC10635067 DOI: 10.1101/2023.11.01.565230. eLife [Accepted peer reviewed publication]. 13:RP94075. DOI: doi.org/10.7554/eLife.94075.3.
  • . Gaedigk A, Turner AJ, Haidar CE, Empey PE, Offer SM. Response to “DPYD genotyping panels: Impact of population diversity.” Clin Transl Sci. 2024 Apr; 17(4):e13806. PMID: 38637962 PMCID: PMC11026573 DOI: 10.1111/cts.13806
  • Turner AJ, Haider CE, Yang W, Boone E, Offer SM, Empey PE, Haddad A, Tahir S, Scharer G, Broeckel U, Gaedigk A. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing. Clin Transl Sci. 2024 Jan;17(1):e13699. PMID: 38129972 PMCID: PMC10777430 DOI: 10.1111/cts.13699.
  • Wen Q, Zhou J, Tian C, Li X, Song G, Gao Y, Sun Y, Ma C, Yao S, Liang X, Kang X, Wang N, Yao Y, Wang H, Liang H, Tang J, Offer SM, Lei X, Yu C, Liu X, Liu Z, Wang Z, Gan H. Symmetric inheritance of parental histones contributes to safeguarding the fate of mouse embryonic stem cells during differentiation. Nat Genet. 2023 Sep;55(9):1555-1566. PMID: 37666989 PMCID: PMC10777717 DOI: 10.1038/s41588-023-01477-w.
  • Ghaffari S, Bouchonville KJ, Saleh E, Schmidt RE, Offer SM#, Sinha S#. BEDwARS: a robust Bayesian approach to bulk gene expression deconvolution with noisy reference signatures. Genome Biology.2023 Aug 3; 24(1):178. PMID: 37537644 PMCID: PMC10399072 DOI: 10.1186/s13059-023-03007-7.
  • Diasio RB, Offer SM. Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5- Fluorouracil Therapy. Cancers. 2022 Jun 30;14(13):3207 PMID: 35804978 PMCID: PMC9264755 DOI: 10.3390/cancers14133207
  • Li X, Zhou J, Zhao W, Wen Q, Wang W, Peng H, Gao Y, Bouchonville KJ, Offer SM, Chan K, Wang Z, Li N, Gan H. Defining Proximity Proteomics of Histone Modifications by Antibody-mediated Protein A-APEX2 Labeling. Genomics Proteomics Bioinformatics. 2021 Sep 30 Epub 2021 Sept 20 PMID: 34555496 DOI: 10.1016/j.gpb.2021.09.003.
  • Diasio RB, Innocenti F, Offer SM. Pharmacogenomic-Guided Therapy in Colorectal Cancer. Clin Pharmacol Ther. 2021 Sep; 110 (3):616-625 Epub 2021 July 10 PMID: 34114648 DOI: 10.1002/cpt.2334.
  • Hamzic S, Scharer D, Offer SM, Meulendijks D, Nakas C, Diasio RB, Fontana S, Wehrli M, Schurch S, Amstutz U, Largiader CR. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. Br J Clin Pharmacol. 2021 Aug; 87 (8):3234-3243 Epub 2021 Mar 30 PMID: 33491253 PMCID: 8359980 DOI: 10.1111/bcp.14742.
  • Wang Z*, Wu R, Nie Q, Bouchonville KJ, Diasio RB, Offer SM. Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance. Journal of the National Cancer Center. 2021 Mar. 1 (1):15-22 DOI: 10.1016/j.jncc.2020.12.003.